1. Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment
- Author
-
E. Aamdal, E. Skovlund, K.D. Jacobsen, O. Straume, C. Kersten, O. Herlofsen, J. Karlsen, I. Hussain, A. Amundsen, A. Dalhaug, M. Nyakas, K.T. Hagene, K. Holmsen, S. Aamdal, S. Kaasa, T.K. Guren, and J.A. Kyte
- Subjects
Cancer Research ,C-Reactive Protein ,L-Lactate Dehydrogenase ,Oncology ,Quality of Life ,Humans ,Prospective Studies ,Prognosis ,Ipilimumab ,Melanoma - Abstract
Background: We have previously reported that the safety and efficacy of ipilimumab in real-world patients with metastatic melanoma were comparable to clinical trials. Few studies have explored health-related quality of life (HRQL) in real-world populations receiving checkpoint inhibitors. This study reports HRQL in real-world patients receiving ipilimumab and assesses the prognostic value of patient-reported outcome measures. Patients and methods: Ipi4 (NCT02068196) was a prospective, multicentre, interventional phase IV trial. Real-world patients (N = 151) with metastatic melanoma were treated with ipilimumab 3 mg/kg intravenously as labelled. HRQL was assessed by the European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire at baseline and after 10-12 weeks. Results: The European Organisation of Research and Treatment of Cancer Quality of Life Questionnaire was completed by 93% (141/151 patients) at baseline, and by 82% at 10-12 weeks. Poor performance status and elevated C-reactive protein (CRP) were associated with worse baseline HRQL. Clinically relevant and statistically significant deteriorations in HRQL from baseline to weeks 10-12 were reported (P
- Published
- 2022